VRPX (Virpax Pharmaceuticals) Total Liabilities: $2.47 Mil (As of Dec. 2024)


What is Virpax Pharmaceuticals Total Liabilities?

Virpax Pharmaceuticals VRPX Total Liabilities is $2.47 Mil as of Dec. 2024.

Virpax Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2024 was $2.47 Mil.

Virpax Pharmaceuticals's quarterly Total Liabilities declined from Jun. 2024 ($5.39 Mil) to Sep. 2024 ($2.36 Mil) but then increased from Sep. 2024 ($2.36 Mil) to Dec. 2024 ($2.47 Mil).

Virpax Pharmaceuticals's annual Total Liabilities increased from Dec. 2022 ($3.10 Mil) to Dec. 2023 ($7.69 Mil) but then declined from Dec. 2023 ($7.69 Mil) to Dec. 2024 ($2.47 Mil).

Virpax Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Virpax Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virpax Pharmaceuticals Total Liabilities Chart

Virpax Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial 4.68 2.09 3.10 7.69 2.47

Virpax Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.69 4.34 5.39 2.36 2.47

Virpax Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Virpax Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.469+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.47

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=1.556--0.914
=2.47

Virpax Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.469+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.47

Total Liabilities=Total Assets (Q: Dec. 2024 )-Total Equity (Q: Dec. 2024 )
=1.556--0.914
=2.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $2.47 Mil mean?
Virpax Pharmaceuticals (VRPX) has a Total Liabilities of $2.47 Mil as of Dec. 2024. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Virpax Pharmaceuticals and its competitors.
Is Virpax Pharmaceuticals' Total Liabilities too high?
Virpax Pharmaceuticals' current Total Liabilities is $2.47 Mil.
How does Virpax Pharmaceuticals' Total Liabilities compare to SYGGF and SCPX?
Virpax Pharmaceuticals' Total Liabilities of $2.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Virpax Pharmaceuticals and its competitors. Virpax Pharmaceuticals's current Total Liabilities is $2.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virpax Pharmaceuticals stock overvalued right now?
Virpax Pharmaceuticals (VRPX) has a current Total Liabilities of $2.47 Mil. The current Total Liabilities is $2.47 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Virpax Pharmaceuticals (VRPX), the current Total Liabilities is $2.47 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Virpax Pharmaceuticals Business Description

Address 1055 Westlakes Drive, Suite 300, Berwyn, PA, USA, 19312
Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.